Abstract
Background
Disease/patient registries are underutilized despite their multiple advantages over clinical trials in the clinical evaluation of drugs, such as the capacity for long-term curation, provision of patient outcome data in routine clinical practice, and provision of benchmark data for comparison. Ensuring the fit-for-purpose quality of data generated from such registries is important to informing regulatory decision making. Here, we report the construction of a quality management system aiming to ensure regulatory-grade data quality for a registry of Japanese patients with glaucoma to evaluate long-term patient outcomes.
Methods
The quality management system was established by reference to the risk-based approach in the ICH-E6 (R2) recommendations. The following three-component approach was taken: establishment of governance, computerized system validation (CSV), and implementation of risk assessment and control. Compliance of the system with the recommendations of regulatory guidelines relevant to use of the registry was assessed.
Results
Governance by academic collaboration was established. This was followed by the development of a total of 15 standard operating procedures, including CSV, data management, monitoring, audit, and management of imaging data. The data management system was constructed based on a data management plan, which specified data/paper flow and data management procedures. The electronic data capture (EDC) system was audited by an external vendor, and configured and validated using the V-model framework as recommended in the GAMP5 guideline. Informed consent, eligibility assessment and major ophthalmology measurements were determined as Critical to Quality (CTQ) factors. A total of 22 risk items were identified and classified into three categories, and operationalized in the form of a risk control plan, which included training sessions and risk-based monitoring. The glaucoma registry addressed most quality recommendations in official guidelines issued by multiple health authorities, although two recommendations were not met.
Conclusions
We established and configured a quality management system for a glaucoma registry to ensure fit-for-purpose data quality for regulatory use, and to curate long-term follow-up data of glaucoma patients in a prospective manner.
Publisher
Public Library of Science (PLoS)
Reference29 articles.
1. GetReal initiatives. https://www.imi.europa.eu/projects-results/project-factsheets/getreal-initiative.
2. Clinical Innovation Network. https://cinc.ncgm.go.jp.
3. 21st Century Cures Act;Michael Gabay;Hosp Pharm,2017
4. U.S. Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision Making for Medical Devices. https://www.fda.gov/media/99447/download.
5. European Medicines Agency. Discussion paper: Use of patient disease registries for regulatory purpose—methodological and operational considerations. https://www.ema.europa.eu/documents/other/discussion-paper-use-patient-disease-registries-regulatory-purposes-methodological-operational_en.docx.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献